세계의 GLP-1 아날로그 시장 : 제품별, 형식별, 투여 경로별, 적응증별 - 예측(-2032년)
GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2032
상품코드:1516916
리서치사:MarketsandMarkets
발행일:2024년 07월
페이지 정보:영문 316 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 GLP-1 아날로그 시장 규모는 2024년 474억 달러로 추정되고, 2032년까지 4,711억 달러에 이를 것으로 예측되며, 예측 기간에 CAGR 33.2%로 성장이 예상됩니다. 시장의 주요 성장 촉진요인은 만성 비만 치료 및 체중 관리에 대한 GLP-1 의약품 클래스의 인기가 높아지고, 2형 당뇨병 치료에 대한 GLP-1 유사체의 높은 효능 등입니다. 게다가 경구 투여형이나 단일 투여 자동 주사기 등 간편한 형태의 GLP-1 의약품의 개발을 중시한 기술 혁신이 시장 성장을 가속할 것으로 예측됩니다.
조사 범위
조사 대상년도
2022-2032년
기준년
2023년
예측 기간
2024-2032년
단위
100만/10억 달러
부문
제품별, 형식별, 투여경로별, 적응증별, 최종 사용자별
대상 지역
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카
'제품별로는 젬바운드(틸제파티드) 제제가 시장에서 가장 빠르게 성장할 것으로 예측됩니다.'
제프바운드는 비만치료제로 승인된 것, 2023년 출시 이후 급격한 수익성장이 확인되고 있는 것, 비만과 체중관리에 대한 틸제파티드의 채용이 확대되고 있는 등의 요인에 의해 예측기간에 가장 빠른 성장이 예상됩니다.
'제품 형식별로는 단일 용량 형식이 시장에서 가장 큰 점유율을 차지했습니다.'
2023년, 단일 용량 형식이 시장의 가장 큰 점유율을 차지했습니다. 이 시장 부문의 성장은 단일 용량 형태가 제공하는 투여 용이성과 주사 횟수가 적고 단일 용량 자동 주사기의 가용성 향상으로 인한 것입니다.
'북미가 시장의 가장 큰 점유율을 차지했습니다.'
북미의 큰 점유율은 정부기관이나 제약 및 바이오테크놀러지 기업에 의한 생물의학 연구에 대한 투자나 자금 제공 증가에 의한 것으로 예상됩니다. 이 지역에서는 GLP-1 제품의 대부분이 입수 가능하기 때문에 신기술과 대체 요법의 조기 채용이 시장 성장을 더욱 뒷받침하고 있습니다. 또한 이 지역에서 여러 시장 진출 기업이 확고한 지위를 구축하고 있는 것도 시장 성장을 지원하는 주요 요인 중 하나입니다. 이러한 주요 기업에는 Eli Lilly and Company(미국), Novo Nordisk A/S(덴마크) 등이 포함됩니다.
'유럽 : 시장에서 두 번째로 큰 지역'
유럽 시장은 GLP-1 아날로그 의약품의 두 번째 시장입니다. 이는 동지역에서 일어나는 다수의 학술기관 및 연구기관의 존재, 시장 진입기업 및 정부기관에 의한 투자 확대, 연구개발 활동에 대한 주목의 고조에 기인합니다.
본 보고서에서는 세계의 GLP-1 아날로그 시장에 대해 조사 분석했으며, 주요한 촉진요인과 억제요인, 경쟁 구도, 장래의 동향등의 정보를 제공합니다.
The GLP-1 Analogues market is expected to reach USD 471.1 billion by 2032 from USD 47.4 billion in 2024, at a CAGR of 33.2% during the forecast period. The key factors driving the growth of the GLP-1 Analogues market include the growing popularity of the GLP-1 drug class for the treatment of chronic obesity and weight management and high efficacy of GLP-1 analogues for treating type 2 diabetes. Additionally, innovation focusing on the development of convenient forms of GLP-1 drugs, such as oral dosage forms and single dose autoinjectors, are expected to drive growth of GLP-1 analogues market.
Scope of the Report
Years Considered for the Study
2022-2032
Base Year
2023
Forecast Period
2024-2032
Units Considered
Million/Billion (USD)
Segments
By Product, Format, Route of Administration, Indication, End User
Regions covered
North America, Europe, Asia Pacific, Latin America, Middle East and Africa
The GLP-1 Analogues market has been segmented based on products, format, route of administration, indication, and end-user.
"By product, Zepbound (tirzepatide) drug is forecasted to grow at the fastest rate in the GLP-1 Analogues market"
Based on product, the GLP-1 Analogues market is categorized into Ozempic (semaglutide), Trulicity (dulaglutide), Mounjaro (tirzepatide), Wegovy (semaglutide), Rybelsus (semaglutide), Saxenda (liraglutide [rDNA origin] injection), Victoza (liraglutide), Xultophy 100/3.6 (insulin degludec and liraglutide injection), Soliqua 100/33 (insulin glargine and lixisenatide injection), Zepbound (tirzepatide), Bydureon (exenatide extended-release), and other products. Zepbound is expected to experience fastest growth during the forecast period owing to factors such as approval of the drug for the treatment of obesity, exponential revenue growth observed since launch of the drug in 2023, and growing adoption of tirzepatide for obesity and weight management.
"By product format, the single dose format segment accounted for the largest share in the GLP-1 Analogues market"
Based on product format, the GLP-1 Analogues market is segmented into single-dose, multi-dose, and tablets. In 2023, the single-dose format segment accounted for the largest share of the GLP-1 Analogues market. Growth in this market segment can be attributed to the ease of administration and lower injection frequencies offered by single-dose format, together with the growing availability of single-dose auto-injectors.
"North America: accounted for the largest share of the GLP-1 Analogues market"
North America accounted for the largest share of the GLP-1 Analogues market. The large share of the North American region can be attributed to growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Early adoption of emerging technologies and alternative therapies, supported by the availability of the majority of GLP-1 products in the region, further supports market growth. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include Eli Lilly and Company (US), Novo Nordisk A/S (Denmark).
"Europe: The second-largest region in the GLP-1 Analogues market."
The Europe GLP-1 Analogues market is the second largest market for GLP-1 Analogue drugs. This is attributed to the presence of a large number of academic and research institutes in this region, growing investments by market players and government institutes, and an increasing focus on research and development activities.
The primary interviews conducted for this report can be categorized as follows:
By Respondent: Supply Side- 70% and Demand Side 30%
By Designation: Managers - 45%, Directors- 30%, and Executives - 25%
By Country: North America- 40%, Europe- 30%, Asia Pacific- 20%, Latin America- 5%, and Middle East and Africa- 5%
Prominent Players
Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), AstraZeneca (UK), Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (China), Boehringer Ingelheim International GmbH (Germany), Innovent (China), Paige Biopharmaceutical (Suzhou) Co., Ltd. (China), Sciwind Biosciences Co., Ltd. (China), Zealand Pharma A/S (Denmark), Beijing Dongfang Baitai Biotechnology Co., Ltd (China), and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China)
Research Coverage:
This report provides a detailed picture of the GLP-1 Analogues market. It aims to estimate the size and future growth potential of the market across different segments, such as the product, product format, route of administration, indication, end user, and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the GLP-1 Analogues market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provides insights on the following pointers"
Analysis of key drivers (Strong R&D pipeline, Improved relative efficacy of GLP-1 drugs), opportunities (Integration of GLP-1 drugs into telehealth and digital weight management programs), restraints (High barriers for new entrants due to duopoly), and challenges (Off-label use of GLP-1 drugs, High non-adherence to therapy after 12-24 months) influencing the growth of the GLP-1 Analogues market.
Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the GLP-1 Analogues market.
Market Development: Comprehensive information about lucrative markets- the report analyses the GLP-1 Analogues market across varied regions.
Market Diversification: Exhaustive information about new drugs, untapped geographies, recent developments, and investments in the GLP-1 Analogues market.
Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 analogues market.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 MARKET SIZE ASSESSMENT
2.3 MARKET GROWTH FORECAST
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 LIMITATIONS
2.7 RISK ANALYSIS
2.8 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 GLP-1 ANALOGUES MARKET OVERVIEW
4.2 NORTH AMERICA: GLP-1 ANALOGUES MARKET SHARE, BY INDICATION AND COUNTRY (2023)
4.3 GLP-1 ANALOGUES MARKET SHARE, BY PRODUCT, 2024 VS. 2032
4.4 GLP-1 ANALOGUES MARKET SHARE, BY INDICATION, 2023
4.5 GLP-1 ANALOGUES MARKET SHARE, BY END USER, 2024 VS. 2032
